ROMERIO, ALESSIO

ROMERIO, ALESSIO  

DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE  

Mostra records
Risultati 1 - 20 di 31 (tempo di esecuzione: 0.026 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Representative secondary PET micro and nanoplastics via ethylene glycol fragmentation (EGF): Physicochemical and immuno-toxicological properties 01 - Articolo su rivista 2026 Shaik M. M.Ami D.Romerio A.Gaboardi M.Natalello A.Peri F. +
Validating Natural Compounds as Toll-Like Receptor 4 (TLR4) Antagonists: Experimental Challenges and Therapeutic Perspectives 01 - Articolo su rivista 2026 Lami F.Romerio A.Peri F. +
Developing New Toll-Like Receptor 4 (TLR4) Modulators As Innovative And Inexpensive Vaccine Adjuvants 02 - Intervento a convegno 2025 Alessio RomerioMohammed M. ShaikAlice ItaliaFederico LamiFrancesco Peri +
Functional impact of Toll-like Receptor 4 (TLR4) modulation in lung fibrosis-associated fibroblasts 02 - Intervento a convegno 2025 Italia, ARomerio, ALami, FGalli,MGranucci, FCosta,B. SPeri, F +
Monosaccharide-Based Synthetic TLR4 Agonist Enhances Vaccine Efficacy against Pseudomonas aeruginosa Challenge 01 - Articolo su rivista 2025 Romerio A.Peri F. +
Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection 01 - Articolo su rivista 2025 Romerio A.Peri F. +
Study on the impact of Toll-like Receptor 4 (TLR4) modulation in rare inflammatory-fibrotic diseases 02 - Intervento a convegno 2025 Italia, AFranco, A. R.Shaik, M. M.Romerio, A.Lami, F.Peri, FCosta , B. S. +
Towards more efficient synthetic immunomodulators: biological characterization and mechanism of action of monosaccharide-derived TLR4 agonists 01 - Articolo su rivista 2025 Franco, A. R.Romerio, A.Italia, A.Lami, F.Shaik, M. M.Artusa, V.Peri, F. +
Design, Synthesis and Biological Evaluation of New Glycolipid-Based Toll-Like Receptor 4 (TLR4) Modulators 02 - Intervento a convegno 2024 Alessio RomerioMohammed M. ShaikAlice ItaliaFrancesco Peri
Design, Synthesis and characterization of synthetic and natural derived TLR4 antagonists 02 - Intervento a convegno 2024 Lami, FRomerio, AItalia, AShaik, M MPeri, F +
Developing New Toll-Like Receptor 4 (TLR4) Modulators as Innovative and Inexpensive Vaccine Adjuvants 02 - Intervento a convegno 2024 Alessio RomerioMohammed M. ShaikAlice ItaliaFederico LamiFrancesco Peri
Development of a New Vaccine Adjuvant System Based on the Combination of the Synthetic TLR4 Agonist FP20 and a Synthetic QS-21 Variant 01 - Articolo su rivista 2024 Shaik M. M.Romerio A.Sesana S.Re F.Bezuidenhout C. X.Bracco S.Peri F. +
Novel TLR4-Activating Vaccine Adjuvant Enhances the Production of Enterococcus faecium-binding Antibodies 01 - Articolo su rivista 2024 Franco, ARRomerio, AArtusa, VShaik, MMItalia, APeri, F +
Study on the impact of Toll-like Receptor 4 (TLR4) modulation in rare inflammatory-fibrotic diseases 02 - Intervento a convegno 2024 Italia, A.Franco , AR.Shaik M. M.Romerio, A.Lami, F.Peri, F.Costa, BS. +
Vibrational spectroscopy coupled with machine learning sheds light on the cellular effects induced by rationally designed TLR4 agonists 01 - Articolo su rivista 2024 Ami D.Franco A. R.Artusa V.Romerio A.Shaik M. M.Italia A.Peri F.Natalello A. +
Cleaner synthesis of preclinically validated vaccine adjuvants 01 - Articolo su rivista 2023 Romerio, APeri, F
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW, GLYCOLIPID-BASED TOLL-LIKE RECEPTOR 4 (TLR4) MODULATORS 02 - Intervento a convegno 2023 Alessio RomerioValentina ArtusaMohammed M. ShaikFederico LamiFrancesco Peri +
Design, synthesis and Biological evaluation of New, glycolipid-based Toll-Like Receptor 4 (TLR4) Modulators 02 - Intervento a convegno 2023 Alessio RomerioMohammed M. ShaikFederico LamiFrancesco Peri +
Impact of Toll-like Receptor 4 (TLR4) chemical modulation by small- molecular antagonists in rare inflammatory-fibrotic diseases 02 - Intervento a convegno 2023 Italia, A.Romerio,A.Shaik, M. M.Costa, B.Peri, F. +
New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants 01 - Articolo su rivista 2023 Romerio, AFranco, ARArtusa, VShaik, MMPeri, F +